JP7657797B2 - TNFαおよびIL-23を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド - Google Patents

TNFαおよびIL-23を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド Download PDF

Info

Publication number
JP7657797B2
JP7657797B2 JP2022533410A JP2022533410A JP7657797B2 JP 7657797 B2 JP7657797 B2 JP 7657797B2 JP 2022533410 A JP2022533410 A JP 2022533410A JP 2022533410 A JP2022533410 A JP 2022533410A JP 7657797 B2 JP7657797 B2 JP 7657797B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
isvd
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022533410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505492A5 (cg-RX-API-DMAC7.html
JP2023505492A (ja
Inventor
ハイディ・ロメラエレ
クリスティアン・アスブラント
アン・ブリジュ
ジーグリット・コルネリス
エリク・ローレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2023505492A publication Critical patent/JP2023505492A/ja
Publication of JP2023505492A5 publication Critical patent/JP2023505492A5/ja
Application granted granted Critical
Publication of JP7657797B2 publication Critical patent/JP7657797B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022533410A 2019-12-06 2020-12-03 TNFαおよびIL-23を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド Active JP7657797B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962944619P 2019-12-06 2019-12-06
US62/944,619 2019-12-06
EP20305056 2020-01-23
EP20305056.2 2020-01-23
EP20000090.9 2020-02-28
EP20000090 2020-02-28
EP20305216 2020-03-02
EP20305216.2 2020-03-02
PCT/EP2020/084430 WO2021110816A1 (en) 2019-12-06 2020-12-03 POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23

Publications (3)

Publication Number Publication Date
JP2023505492A JP2023505492A (ja) 2023-02-09
JP2023505492A5 JP2023505492A5 (cg-RX-API-DMAC7.html) 2023-12-07
JP7657797B2 true JP7657797B2 (ja) 2025-04-07

Family

ID=73642903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533410A Active JP7657797B2 (ja) 2019-12-06 2020-12-03 TNFαおよびIL-23を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド

Country Status (14)

Country Link
US (4) US20210188963A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069733A1 (cg-RX-API-DMAC7.html)
JP (1) JP7657797B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220122652A (cg-RX-API-DMAC7.html)
CN (1) CN114981300B (cg-RX-API-DMAC7.html)
AU (1) AU2020396204A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022009799A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163877A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022009239A2 (cg-RX-API-DMAC7.html)
IL (1) IL293561A (cg-RX-API-DMAC7.html)
MX (1) MX2022006880A (cg-RX-API-DMAC7.html)
PH (1) PH12022551214A1 (cg-RX-API-DMAC7.html)
TW (1) TW202134269A (cg-RX-API-DMAC7.html)
WO (1) WO2021110816A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
WO2020144164A1 (en) 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
EP4069733A1 (en) 2019-12-06 2022-10-12 Ablynx N.V. POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFalpha AND IL-23
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
EP4438614A1 (en) 2023-03-31 2024-10-02 Sanofi Methods for purifying heteromultimeric antibodies
US20250236673A1 (en) * 2023-12-22 2025-07-24 Ablynx N.V. Protein-based carriers for site-specific amine conjugation
CN118687298A (zh) 2024-07-29 2024-09-24 上海原能细胞生物低温设备有限公司 一种立式低温存储冰箱
CN119371530B (zh) * 2024-11-06 2025-05-20 北京科道博济生物科技有限公司 一种靶向il-23a的纳米抗体及其应用
CN121824755A (zh) * 2026-01-16 2026-04-10 天津科道博济生物科技有限公司 一种靶向il-23a的纳米检测抗体及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068627A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2015173325A2 (en) 2014-05-16 2015-11-19 Ablynx Nv Improved immunoglobulin variable domains
WO2017081320A1 (en) 2015-11-12 2017-05-18 Ablynx Nv Improved tnf binders
WO2017137579A1 (en) 2016-02-12 2017-08-17 Ablynx Nv Method for the production of immunoglobulin single variable domains
JP2017533705A (ja) 2014-11-05 2017-11-16 イーライ リリー アンド カンパニー 抗tnf−/抗il−23二重特異性抗体
WO2019027780A1 (en) 2017-08-02 2019-02-07 Eli Lilly And Company BISPECIFIC ANTI-TNF- / ANTI-IL-23 IGG ANTIBODIES

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン.ヴェー. Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
LT3466972T (lt) 2011-06-23 2026-06-25 Ablynx Nv Serumo albuminą surišantys baltymai
EP3365371B1 (en) * 2015-10-22 2025-10-08 Ablynx NV Gitr agonists
HUE057241T2 (hu) 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
EP4442709A3 (en) 2017-01-17 2024-12-25 Ablynx NV Improved serum albumin binders
EP4069733A1 (en) 2019-12-06 2022-10-12 Ablynx N.V. POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFalpha AND IL-23

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068627A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2015173325A2 (en) 2014-05-16 2015-11-19 Ablynx Nv Improved immunoglobulin variable domains
JP2017533705A (ja) 2014-11-05 2017-11-16 イーライ リリー アンド カンパニー 抗tnf−/抗il−23二重特異性抗体
WO2017081320A1 (en) 2015-11-12 2017-05-18 Ablynx Nv Improved tnf binders
WO2017137579A1 (en) 2016-02-12 2017-08-17 Ablynx Nv Method for the production of immunoglobulin single variable domains
WO2019027780A1 (en) 2017-08-02 2019-02-07 Eli Lilly And Company BISPECIFIC ANTI-TNF- / ANTI-IL-23 IGG ANTIBODIES

Also Published As

Publication number Publication date
US11332525B2 (en) 2022-05-17
CN114981300B (zh) 2025-10-31
US12528860B2 (en) 2026-01-20
EP4069733A1 (en) 2022-10-12
US20220064281A1 (en) 2022-03-03
TW202134269A (zh) 2021-09-16
PH12022551214A1 (en) 2023-10-09
AU2020396204A1 (en) 2022-07-28
KR20220122652A (ko) 2022-09-02
BR112022009799A2 (pt) 2022-08-16
US20220363747A1 (en) 2022-11-17
CN114981300A (zh) 2022-08-30
WO2021110816A1 (en) 2021-06-10
US20210188963A1 (en) 2021-06-24
CA3163877A1 (en) 2021-06-10
IL293561A (en) 2022-08-01
US20220372128A1 (en) 2022-11-24
JP2023505492A (ja) 2023-02-09
CO2022009239A2 (es) 2022-07-29
MX2022006880A (es) 2022-07-11

Similar Documents

Publication Publication Date Title
CN114981300B (zh) 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
TWI861302B (zh) 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽
JP7719775B2 (ja) TNFαおよびOX40Lを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
US12509522B2 (en) Polypeptides comprising immunoglobulin single variable domains targeting il-13 and OX40L
US11897951B2 (en) Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
TW202342508A (zh) 包含靶向TCRαβ、CD33和CD123的免疫球蛋白單可變結構域的多肽
CN117820475A (zh) 针对il-17a的新型纳米抗体、药物、制备、方法及应用
RU2846433C1 (ru) Полипептиды, содержащие одиночные вариабельные домены иммуноглобулинов, нацеливающиеся на tnfa и ox40l
RU2836310C1 (ru) Полипептиды, содержащие одиночные вариабельные домены иммуноглобулинов, нацеливающиеся на il-13 и tslp

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250326

R150 Certificate of patent or registration of utility model

Ref document number: 7657797

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150